We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Atrium Health Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
Nilanjan Ghosh, MD, PhD, is the chair of hematology and chief of the lymphoma division at Atrium Health Levine Cancer Institute, Charlotte, NC, USA. He also serves as a clinical professor of medicine at the Wake Forest School of Medicine, Winston-Salem, and is a member of the Wake Forest Comprehensive Cancer Center. read more
He received his medical degree at K.J. Somaiya Medical College and Research Center at the University of Mumbai, India, and his doctoral degree in biochemistry and molecular biology at the University of South Florida, Tampa, FL. He completed his residency in internal medicine at Long Island Jewish Medical Center, Queens, NY, and a fellowship in haematology and oncology at Johns Hopkins University, Baltimore, MD.
Dr Ghosh’s research interests include lymphoma, chronic lymphocytic leukaemia, chimeric antigen receptor T-cell therapy, stem cell transplant, development of novel therapies and overcoming disparities in healthcare. He has published numerous research papers in prestigious journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology and JAMA Oncology.
Dr Ghosh has served as a principal investigator and on steering committees for multiple clinical trials in the field of lymphoma. He is the recipient of several awards, including from the American Society of Clinical Oncology and the Leukemia Lymphoma Society.
Dr Nilanjan Ghosh discloses: Advisory board or panel fees from Roche NHL Solutions Panel. Consultancy fees from AbbVie, Adaptive Biotech (relationship terminated), ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Genmab, Gilead Sciences, Incyte, Janssen, Kite Pharma, Lava Therapeutics (relationship terminated), Loxo Oncology, Novartis, Pharmacyclics, Roche/Genentech, Seagen and TG Therapeutics (relationship terminated). Grants/research support from AbbVie, Bristol Myers Squibb, Gilead Sciences, MorphoSys, Pharmacyclics, Roche/Genentech and TG Therapeutics. Speakers bureau fees from AstraZeneca, Bristol Myers Squibb, Epizyme, Janssen, Kite Pharma and Pharmacyclics (all relationships terminated).
The David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USA
Peter Riedell, MD, is an assistant professor of medicine and also serves as the director of clinical research for the Hematopoietic Cellular Therapy Program, and associate director of the David and Etta Jonas Center for Cellular Therapy at the University of Chicago, Chicago, IL, USA.read more
Dr Riedell specializes in the care of adults with lymphomas and chronic lymphocytic leukaemia. In particular, he has a special interest in the use of chimeric antigen receptor T-cell therapy in the treatment of these conditions.
As an active clinical researcher, Dr Riedell serves as the principal investigator on several national and international clinical trials evaluating the role of targeted therapies, stem cell transplantation and cellular therapy in the treatment of lymphoma. He has been heavily involved in the development and implementation of therapies that harness a patient’s own immune system to fight cancer. His research aims to better characterize and enhance the safety and effectiveness of cellular therapy in order to improve patient outcomes.
Dr Riedell holds roles on several national committees related to lymphoma and cellular therapy, and he is active in both patient and physician education. He also serves on the editorial board for peer-reviewed journals and is a member of the American Society of Hematology, the American Society of Clinical Oncology and the American Society of Transplantation and Cellular Therapy.
Dr Peter Riedell discloses: Advisory board or panel fees from ADC Therapeutics, BeiGene, Bristol Myers Squibb, Genmab, Intellia Therapeutics, Janssen, Kite Pharma/Gilead, Nektar Therapeutics, Novartis and Nurix Therapeutics. Consultancy fees from Abbvie, Bristol Myers Squibb, CVS Caremark, Pharmacyclics, Sana Biotechnology. Grants/research support from Calibr, Celgene/Bristol Myers Squibb, CRISPR Therapeutics, Fate Therapeutics, Kite Pharma, MorphoSys, Nkarta, Novartis, Tessa Therapeutics, Roche and Xencor. Speakers bureau fees from Kite Pharma (relationship terminated).
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Or use a
.Explore the latest in medical education and stay current in your field. Create a free account to track your learning.